Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease

Journal of Cardiovascular Pharmacology

Volumn 38, Issue 4, 2001, Pages 633-641

  Amoroso, Giovanni ^a   Van Boven, Ad J ^a   Van Veldhuisen, Dirk J ^a   Tio, Reń A ^a   Baljé Volkers, Corine P ^a   Petronio, Anna S ^b   Van Oeveren, Wim ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Coronary disease; Inhibitors; Platelets; Receptors; Stents

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; INDOMETACIN; SODIUM CHLORIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ACTIVITY; DRUG BINDING; DRUG EFFICACY; FEMALE; FLUORESCENCE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOSIS;

ANTIBODIES, MONOCLONAL; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; STATISTICS, NONPARAMETRIC; STENTS; THERAPEUTIC EQUIVALENCY;

EID: 0034828203     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200110000-00016     Document Type: Article

References (36)

1. Continued benefit of coronary stenting versus balloon angioplasty: One-year clinical follow-up of Benestent trial
2. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): A four-year follow-up
3. Subacute stent thrombosis in the era of intravascular ultrasound guided coronary stenting without anticoagulation: Frequency, predictors, and clinical outcome
4. Stent thrombosis: Historical perspectives and current trends
5. Impact of patient characteristics, complications, and facility volume on the costs and time of cardiac catheterization and coronary angioplasty in 70 catheterization laboratories
6. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance
7. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
8. Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis
9. Porcine model of stent thrombosis: Platelets are the primary component of stent closure
10. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators
11. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II
12. Routine use of abciximab in coronary stenting?
13. IIb's are not IIb's
14. Platelet glycoproteins IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use?
15. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization
16. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
17. A whole blood assay of inhibition of platelet aggregation by glycoprotein Iib/IIIa antagonists: Comparison with other aggregation methodologies
18. Enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
19. Differential effects of oral administrations to human volunteers of acetylsalicylic acid, sodium salicylate and indomethacin on 12-hydroxyeicosatetraenoic acid formation by stimulated platelets
20. Silicon-carbide coated coronary stents have low platelet and leukocyte adhesion during platelet activation
21. Europium as a label in time-resolved immunofiuorometric assays
22. Platelet glycoprotein Iib/IIIa receptors in cardiovascular medicine
23. Perspectives series: Cell adhesion in vascular biology: Von Willebrand factor
24. Adhesion of ADP-activated platelets to intact endothelium under stagnation point flow in vitro is mediated by the integrin alphaIIbeta3
25. Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins: RGD-containing peptides from viper venoms
26. C7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GpIIb/IIIa as well as endothelial vitronectin receptor: Results from patients with acute myocardial infarction and healthy controls
27. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-Iib/IIIa blockade: Evaluation of platelet Iib/IIIa inhibitor for stenting
28. Acute antithrombotic effect of a front-loaded regimen of Clopidogrel in patients with atherosclerosis on aspirin
29. Clopidogrel: The future choice for preventing platelet activation during coronary stenting?
30. Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro
31. Altered platelet function detected by flow cytometry: Effects of coronary artery disease and age
32. Platelet surface activation antigen expression at baseline and during elective angioplasty in patients with mild to moderate coronary artery disease
33. Relation between carotid intima-media thickness, platelet surface activation and endothelial cell markers
34. Consequences of the interaction of platelet membrane glycoprotein GPIIb-IIIa (alpha IIb beta 3) and its ligands
35. Flow cytometric analysis of coronary stent-induced alterations of platelet antigens in an in vitro model
36. Expression of markers of platelet activation and the interpatient variation in response to abciximab